Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. - Wikidata - awgldk - TriplyDB

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

http://www.wikidata.org/entity/Q35638594

about

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept.A comparative study between clinical grading of anterior chamber flare and flare reading using the Kowa laser flare meter.Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Update on the treatment of ankylosing spondylitis.Review of Systemic Immunosuppression for Autoimmune Uveitis Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.Long-term use of adalimumab in the treatment of rheumatic diseases.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Pharmacotherapy of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Biologic agents in inflammatory eye disease.Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy.Uveitis in seronegative arthritis.The role of biologic agents in the management of non-infectious uveitis.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Ocular inflammatory diseases associated with rheumatoid arthritis.Paradoxical effects of anti-TNF-α agents in inflammatory diseases.Biological therapies for spondyloarthritis.Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye.Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.Efficacy and safety of adalimumab in ankylosing spondylitis.Use of biologic agents in ocular manifestations of rheumatic disease.Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis.Adalimumab in the therapy of uveitis in childhood Adalimumab for the treatment of ankylosing spondylitis.Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.Management of Uveitis in Spondyloarthropathy: Current Trends.Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review.[Uveitis in spondyloarthritis].Ocular involvement in patients with spondyloarthritis.Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study.[Anti-TNF-α treatment for uveitis. Analysis of the current situation].Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?

P2860

Q26738918-AD2CA0C7-8407-4C7F-9622-7A5EBA5DA9FB Q26777084-2D8D258F-5662-4DEE-B1C1-8CBE9BEE09DD Q33786723-6C921E78-4910-46E6-B6B4-BCCAEB338501 Q34362284-DC47A9C3-E30F-4D46-A8F4-5AC7BE4971CC Q34449888-A8F6C579-1F28-4F3F-9E29-1497A6EB7521 Q34592673-BF3420AD-B92A-4D24-9670-01A149B29FE3 Q34627012-9FEA5197-46DF-43F0-A8ED-4D11849DA89C Q35608168-22883519-A277-4012-AB82-BFE7F73FBA49 Q36171750-FD9837B4-EA32-43C7-B24E-6B049BC4EEBB Q37105146-5400C97D-A888-48D6-B14D-B131F97AF851 Q37146227-E7029979-9E24-45A7-ABCD-8A3A1767FAB5 Q37358124-86BA1849-D4CE-48F5-82A2-C2E9131AC1A3 Q37650221-F7A52D04-EB7E-4C54-895D-D892AA78AD08 Q37724245-6BDF9A0C-7E57-420A-BD6D-73F474EA9296 Q37756167-C81E2CF4-3736-4747-9899-B05476E199A9 Q37997772-3A731DFA-A25B-49B3-8CF7-847DF6F85EF3 Q38012490-2D13720E-DB78-4AD7-841B-524FF117401D Q38021939-DB86B867-B6DF-446A-B02A-45B0A859DD57 Q38025152-E1DFE8F2-0259-4A06-A9A6-25EE9A72863E Q38074446-BBA415A1-6188-425C-AEFF-D9037CFE0DFF Q38169978-9A96CE32-53A0-40CD-A803-73E15A5567A6 Q38170158-35697257-F30E-4D93-B94A-3E0F40891FCB Q38217223-9260A372-33B1-402D-952D-6274C32422D4 Q38559007-619A7F00-68F0-4C8A-BB19-D982F45A6A2D Q38968166-EF37C07A-E30E-442C-9EF4-7354FC04795A Q38993324-3D2811B3-ADB5-4036-AAFC-062F4B6684CD Q40008319-B9D6714D-7CEF-4415-ADDB-65ECECD8D9E9 Q40554011-E7DE3777-B0EB-4868-819D-E4A6084E1B4C Q42589744-9D10F529-0559-4C32-A860-4C647C8AED88 Q42616837-152DF8ED-DEDB-40BD-AE16-EF5D19D04EB8 Q44236777-A6ECE112-77AA-46D9-98D6-8BAEB59805C5 Q47137068-58DB33BE-477D-4C37-A82B-55575BC3F9E3 Q47378653-2AC6BC83-6137-465E-9372-A47472BAD718 Q50502651-A5EDE4F7-9D76-458E-80AB-505EA951B54E Q51087775-B5BF8803-9382-4B33-AF30-C26546CBEA2F Q51317600-A47FBA5D-87B3-4EAC-9D35-F202409DEA9B Q52899661-D735D176-80BD-4ED7-8B93-D908BF802924 Q53720966-0777CFAF-6EAD-4C9B-917D-5E204A8B959D Q54546316-A3121A82-DC1A-4681-9435-E630626E7AA0

P2860

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

http://www.wikidata.org/entity/Q35638594

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@ast

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@en

type

label

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@ast

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@en

prefLabel

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@ast

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@en

P1433

Q35638594-DE6EA39C-B35B-4C84-B1A0-F1E50074866A

P1476

Q35638594-756600BF-FD3C-4811-8E91-E899BFA31237

P2093

Q35638594-4B06D63A-7B9D-47D0-93B5-A68CE66B288C

Q35638594-60F76A5E-A10E-4AB9-B2E4-89BFFEB1EC93

Q35638594-7F35DA18-6262-4E8A-B019-7ABFA9EAFAB2

Q35638594-8C0D526A-06D8-41DF-AB9A-559DE5D120B2

Q35638594-9AC79007-80B1-4AFD-B51B-E5DE82D1B3C6

Q35638594-9C26FF06-90D8-4799-8697-5FB72AF76056

Q35638594-BF48873A-00B3-4E74-8C1C-E730B48F1E41

P2860

Q35638594-00150CC3-F0BF-496B-87CB-793ACC51C326

Q35638594-0708CC12-D8F8-496D-A955-4A38DF6599DB

Q35638594-2139DC6A-CA99-475B-9FA8-43685A8BB4FF

Q35638594-4B476049-41B3-4962-A6E2-4B5B4A158367

Q35638594-56C29E3E-4FEE-4F1D-9FD7-28B7FDC634C4

Q35638594-871D086E-AEC6-4CF5-8EB2-876339FC4CE8

Q35638594-943A37E2-C493-4E65-B1D0-1EA48DB8D4E8

Q35638594-BC1B6A0A-C332-4119-A762-046E82204EAB

Q35638594-DCF0998A-0CB6-4794-86B2-BFCABBC09B5C

Q35638594-F410CF19-A0CA-4D68-93B4-9A2F633FFAB9

P304

Q35638594-FBD4E91C-82D2-4BA8-A96E-03DA44D1843F

P31

Q35638594-D7559837-5F62-47E3-9014-B1C3CA197D6D

P356

Q35638594-C64074C2-E79A-4537-B738-E306A699B758

P407

Q35638594-1AC38F4B-5B7B-416A-8650-44FE3ED4CFFC

P433

Q35638594-312210BC-374D-44C7-BBBD-4295855C45E3

P478

Q35638594-F7C728A6-AB95-4E09-95E4-6378883652D8

P577

Q35638594-1B7689A8-545B-403D-BB42-4D556FCA0BC1

P5875

Q35638594-8FF2A9D1-B32A-4F45-8154-D45CD4635533

P698

Q35638594-FB14820C-D219-4983-AC66-496F197712C0

P921

Q35638594-636E57CF-2F6A-44E1-8BF6-F9298A4D26A2

Q35638594-b400fed3-429c-4671-ac17-cda987735193

P932

Q35638594-90CD3757-64D9-4CAB-9E20-E4F9378BEC3B

P356

ARD.2006.052092

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy of tumour necrosis fa ...... opathy: a retrospective study.

@en

P2093

A Ruyssen-Witrand

http://www.w3.org/2001/XMLSchema#string

C Salliot

http://www.w3.org/2001/XMLSchema#string

L Gossec

http://www.w3.org/2001/XMLSchema#string

M Dougados

http://www.w3.org/2001/XMLSchema#string

M Duclos

http://www.w3.org/2001/XMLSchema#string

M Luc

http://www.w3.org/2001/XMLSchema#string

S Guignard

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

An assessment of clinically useful measures of the consequences of treatment

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.

Degree, duration, and causes of visual loss in uveitis.

Why do anti-tumor necrosis factor antibodies work in Crohn's disease?

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

[The treatment of recurrent uveitis with TNF-alpha inhibitors]

Development of Crohn's disease in a patient taking etanercept.

P304

1631-1634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2006.052092

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6885290

http://www.w3.org/2001/XMLSchema#string

P698

16901960

http://www.w3.org/2001/XMLSchema#string

P921

P932

1798480

http://www.w3.org/2001/XMLSchema#string